Dusigitumab
Jump to navigation
Jump to search
This article needs additional citations for verification. (February 2023) |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | IGF2 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6372H9824N1700O2016S54 |
Molar mass | 144233.81 g·mol−1 |
Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGF2.[1][2] It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.[3] Its development has been discontinued.[2]
References
- ^ "Dusigitumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
- ^ a b Osher E, Macaulay VM (August 2019). "Therapeutic Targeting of the IGF Axis". Cells. 8 (8): 895. doi:10.3390/cells8080895. PMC 6721736. PMID 31416218.
- ^ "Dusigitumab - MedImmune". AdisInsight. Springer Nature Switzerland AG.
Categories:
- Articles with short description
- Short description matches Wikidata
- Articles needing additional references from February 2023
- All articles needing additional references
- Drugs not assigned an ATC code
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- Monoclonal antibodies
- Experimental cancer drugs
- Drugs developed by AstraZeneca
- All stub articles
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs